( make up the blood. Circadian: a circad...)Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur,Health

make up the blood.
Circadian: a circadian rhythm is a roughly 24-hour cycle in the physiological processes of living beings.
Compliance: a patient's adherence to a recommended course of treatment.
DBP: diastolic blood pressure.
Diastolic blood pressure: the lowest pressure within the arterial blood stream occurring during each heart beat. The term “diastolic" is used
to refer to the relaxation of the heart between muscle contractions.
Double-blind: a set-up often applied in clinical trials where neither the doctor nor the patient knows if placebo or the active drug
substance is applied.
Enzyme: protein that acts as a catalyst and enables or enhances chemical reactions within cells.
Half-life: time required in which half the amount of a biological substance (e.g. antibodies) is removed from the organism.
Hypertension: high blood pressure.
Intracerebral hemorrhage: occurs when a diseased blood vessel within the brain bursts, allowing blood to leak inside the brain. The most
common cause of intracerebral hemorrhage is high blood pressure.
mm Hg: blood pressure values are universally stated in millimetres of mercury (mm Hg).
Myocardial infarction: commonly known as a heart attack; is a disease state that occurs when the blood supply to a part of the heart is
interrupted.
Peptide: a fragment of a protein comprised of two or more amino acids.
Phase IIa: a clinical trial that examines a new drug candidate’s safety and exploratory efficacy and may involve between 10 and 100
patients.
Placebo: dummy medical treatment.
Plasma renin concentration (PRC): refers to the concentration of renin in the plasma; does not include prorenin, which is the precursor
molecule of renin.
RAS: renin-angiotensin system. A hormone system that regulates long-term blood pressure and blood volume in the body.
Receptor: a protein molecule that binds an
'"/>




Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
2. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
3. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
4. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
5. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
6. Hypertension Education Foundation Survey Results Announced At American Society For Hypertension Annual Meeting Suggests Improved Control Of High Blood Pressure, But Misconceptions Still Exist
7. New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard Therapy in Treatment of Hypertension
8. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
9. King Pharmaceuticals Announces Plan to Present Results from Phase III Clinical Trial Evaluating ALTACE as Monotherapy and in Combination with Hydrochlorothiazide at the American Society of Hypertension Annual Meeting
10. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine